PDS Biotechnology Corporation reports developments in targeted cancer immunotherapies based on its Versamune platform. Company news centers on PDS0101, also called Versamune HPV, in HPV16-positive head and neck cancer, and on PDS01ADC, an IL-12 fused antibody drug conjugate and tumor-targeted immunocytokine evaluated across multiple solid tumor indications.
Recurring updates include clinical-trial data, National Cancer Institute-led study presentations, FDA and IND protocol communications, scientific publications, patent coverage for core technology, quarterly financial results, and broader corporate-program updates.
PDS Biotechnology (Nasdaq: PDSB), a late-stage immunotherapy company specializing in cancer treatment, announced its participation in the A.G.P. Virtual Annual Healthcare Company Showcase on May 21, 2025. CEO Frank Bedu-Addo will engage in a fireside chat from 5:20 to 5:40 p.m. ET. The virtual event will provide opportunities for one-on-one investor meetings with the PDS Biotech leadership team. A replay and transcript of the fireside chat will be available on the company's website after the event.
PDS Biotechnology (PDSB), a late-stage immunotherapy company focused on cancer treatment, has granted a nonstatutory stock option to a new clinical department employee. The inducement grant, issued on May 5, 2025, allows the purchase of 5,000 shares of common stock at an exercise price of $1.31 per share. The stock option follows a four-year vesting schedule, with 25% vesting after the first year and the remaining shares vesting monthly over the subsequent 36 months, contingent on continued employment.
PDS Biotechnology (Nasdaq: PDSB), a late-stage immunotherapy company specializing in cancer treatment, has scheduled its Q1 2025 financial results conference call and webcast for May 14, 2025, at 8:00 AM ET. The company will present its financial performance for the quarter ending March 31, 2025, along with updates on its clinical programs. Investors can join via phone (1-877-704-4453 domestic, 1-201-389-0920 international) or through the webcast. The presentation will be archived on PDS Biotech's website for six months following the live event.
PDS Biotechnology (NASDAQ: PDSB) has announced the acceptance of three abstracts featuring Versamune® HPV (PDS0101) for presentation at the 2025 ASCO Annual Meeting in Chicago from May 30-June 3, 2025.
The presentations include:
- VERSATILE-003: A Phase 3 randomized trial comparing PDS0101 and Pembrolizumab vs. Pembrolizumab alone for first-line treatment of HPV16-positive recurrent/metastatic head and neck cancer
- VERSATILE-002: Results on overall survival in HPV16 positive recurrent/metastatic head and neck cancer patients treated with PDS0101 and Pembrolizumab
- MC200710: Initial results of PDS0101 alone or with pembrolizumab in locally advanced HPV-associated oropharyngeal carcinoma
PDS Biotechnology (Nasdaq: PDSB) announced that preclinical immune response data for their novel Infectimune®-based flu vaccine will be presented at the IMMUNOLOGY2025™ Annual Meeting in Honolulu, Hawaii, from May 3-7, 2025.
The presentation, titled 'Broadly Protective Immunity against Influenza and Opportunities for Universal Influenza Vaccines,' will be delivered by Dr. Andrea Sant from the University of Rochester Medical Center during the International Society of Influenza and Other Respiratory Viruses Symposium on May 4, 2025.
Additionally, the company announced the withdrawal of an abstract titled 'Alterations in peripheral T stem-like memory cells in patients with advanced solid tumors treated with tumor-targeting IL-12 therapy' from the American Association for Cancer Research Annual Meeting 2025 due to new NIH policies regarding employee attendance at scientific conferences.
PDS Biotechnology (NASDAQ: PDSB), a late-stage immunotherapy company, announced that the National Cancer Institute (NCI) will present clinical data on PDS01ADC, their IL-12 fused antibody drug conjugate, at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2025.
The presentation, scheduled for April 29, 2025, will focus on alterations in peripheral T stem-like memory cells in patients with advanced solid tumors treated with tumor-targeting IL-12 therapy. The poster session, titled 'Immune Response to Therapies,' will be presented by Meghali Goswami, Postdoctoral Fellow at The National Institutes of Health.